Experimental toxoplasmosis in Balb/c mice. Prevention of vertical disease transmission by treatment and reproductive failure in chronic infection.
In a study of congenital transmission during acute infection of Toxoplasma gondii, 23 pregnant Balb/c mice were inoculated orally with two cysts each of the P strain. Eight mice were inoculated 6-11 days after becoming pregnant (Group 1). Eight mice inoculated on the 10th-15th day of pregnancy (Group 2) were treated with 100 mg/kg/day of minocycline 48 h after inoculation. Seven mice inoculated on the 10th-15th day of pregnancy were not treated and served as a control (Group 3). Congenital transmission was evaluated through direct examination of the brains of the pups or by bioassay and serologic tests. Congenital transmission was observed in 20 (60.6%) of the 33 pups of Group 1, in one (3.6%) of the 28 pups of Group 2, and in 13 (54.2%) of the 24 pups of Group 3. Forty-nine Balb/c mice were examined in the study of congenital transmission of T. gondii during chronic infection. The females showed reproductive problems during this phase of infection. It was observed accentuated hypertrophy of the endometrium and myometrium. Only two of the females gave birth. Our results demonstrate that Balb/c mice with acute toxoplasmosis can be used as a model for studies of congenital T. gondii infection. Our observations indicate the potential of this model for testing new chemotherapeutic agents against congenital toxoplasmosis.
Fux
B
B
Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, 31270-901, Brasil.
Ferreira
A
A
Cassali
G d
Gd
Tafuri
W L
WL
Vitor
R W
RW
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004195:Disease Models, Animal; D004717:Endometrium / Q000473:pathology; D005260:Female; D006984:Hypertrophy; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008911:Minocycline / Q000627:therapeutic use; D009215:Myometrium / Q000473:pathology; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D014125:Toxoplasmosis, Congenital / Q000517:prevention & control / Q000635:transmission*; D014599:Uterus / Q000473:pathology
D000900:Anti-Bacterial Agents; D008911:Minocycline